Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division cut its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 41.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,463 shares of the biotechnology company's stock after selling 4,621 shares during the quarter. Moody National Bank Trust Division's holdings in Axon Enterprise were worth $3,399,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in AXON. Fourth Dimension Wealth LLC bought a new stake in shares of Axon Enterprise during the 4th quarter valued at $30,000. New Wave Wealth Advisors LLC purchased a new position in shares of Axon Enterprise in the 4th quarter worth $40,000. Y.D. More Investments Ltd purchased a new position in shares of Axon Enterprise in the 4th quarter worth $45,000. Elequin Capital LP purchased a new position in shares of Axon Enterprise in the 4th quarter worth $46,000. Finally, Stonebridge Financial Group LLC purchased a new position in shares of Axon Enterprise during the 4th quarter worth about $53,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

AXON stock traded down $7.71 during trading on Tuesday, hitting $750.86. The stock had a trading volume of 221,914 shares, compared to its average volume of 733,616. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The company's 50-day moving average price is $624.56 and its two-hundred day moving average price is $611.72. The stock has a market capitalization of $58.46 billion, a P/E ratio of 194.02, a PEG ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $766.26.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period last year, the company earned $1.15 EPS. As a group, research analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group raised their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. Barclays upped their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Finally, Needham & Company LLC raised their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Axon Enterprise presently has an average rating of "Moderate Buy" and a consensus target price of $652.73.

Insider Activity

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the transaction, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Brittany Bagley sold 3,400 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the transaction, the chief financial officer now directly owns 131,833 shares in the company, valued at approximately $92,283,100. The trade was a 2.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,969 shares of company stock worth $25,349,594. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.